After a solid two-year run, Gilead Sciences (NASDAQ:GILD) has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from AbbVie (NYSE:ABBV)and Merck (NYSE:MRK) around the corner.

In the slideshow below, you'll find three reasons investors are down on Gilead Sciences and thoughts on the biotech's future.

More companies poised for incredible growth
You can uncover David Gardner's scientific approach to crushing the market and his carefully chosen six picks for ultimate growth in a premium report available for free today. Click here now for access.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.